Skip to content

Study · Randomized controlled trial · n = 218 · 1995

3 results

Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial.

Montorsi M, Zago M, Mosca F, Capussotti L, Zotti E, Ribotta G, Fegiz G, Fissi S, Roviaro G, Peracchia A

Surgery1 Jan 1995Cited by 198 (Europe PMC)

PMID7809832 (opens in a new tab)DOI10.1016/s0039-6060(05)80225-9 (opens in a new tab)PepBankPUB-07809832
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    After elective pancreatic resection, pancreatic fistula occurred in 9% with octreotide versus 19.6% with placebo (p < 0.05).

    In plain wordsAfter elective pancreatic resection, octreotide reduced pancreatic fistulas versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreasePancreatic fistula
    Study

    n = 218

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Pancreatic fistula incidence
    9 percent
    octreotide group
    Pancreatic fistula incidence
    19.6 percent
    placebo group
    Pancreatic fistula incidence
    14.2 percent
    all patients
    Patients with pancreatic fistula
    31 patients
    all patients
    P value
    < 0.05
    pancreatic fistula

    Source sentences

    Summary
    A pancreatic fistula occurred in 31 patients (14.2%), 9% in the octreotide group and 19.6% in the placebo group (p < 0.05).
    2 context sentences
    Summary · context
    A prospective, randomized controlled clinical trial was conducted in 33 Italian surgical departments with the aim of evaluating the efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections.
    Summary · context
    Fifty-four dropped out because of unresectable disease and six were excluded because of protocol violation; the remaining 218 were randomly assigned to the octreotide group (n = 111) or to the placebo group (n = 107).
  2. 02HumanRandomized controlled trialEfficacy outcome

    After elective pancreatic resection, morbidity was 21.6% with octreotide versus 36.4% with placebo (p < 0.05).

    In plain wordsAfter elective pancreatic resection, octreotide reduced morbidity versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseMorbidity
    Study

    n = 218

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Morbidity rate
    21.6 percent
    octreotide group
    Morbidity rate
    36.4 percent
    placebo group
    P value
    < 0.05
    morbidity

    Source sentences

    Summary
    Morbidity rate was significantly lower in the octreotide (21.6%) than in the placebo group (36.4%) (p < 0.05).
    2 context sentences
    Summary · context
    A prospective, randomized controlled clinical trial was conducted in 33 Italian surgical departments with the aim of evaluating the efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections.
    Summary · context
    Fifty-four dropped out because of unresectable disease and six were excluded because of protocol violation; the remaining 218 were randomly assigned to the octreotide group (n = 111) or to the placebo group (n = 107).
  3. 03HumanRandomized controlled trialEfficacy outcome

    After elective pancreatic resection, grouped pancreatic complications occurred in 15.3% with octreotide versus 29.9% with placebo (p < 0.05).

    In plain wordsAfter elective pancreatic resection, octreotide reduced grouped pancreatic complications versus placebo.

    Peptide
    Octreotide
    Outcome
    DecreaseGrouped pancreatic complications
    Study

    n = 218

    Comparator
    Placebo
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    Grouped pancreatic complications
    15.3 percent
    octreotide group
    Grouped pancreatic complications
    29.9 percent
    placebo group
    P value
    < 0.05
    grouped pancreatic complications

    Source sentences

    Summary
    When specific pancreatic complications were grouped together and evaluated, they occurred less frequently in the treated (15.3%) than in the placebo group (29.9%) (p < 0.05).
    2 context sentences
    Summary · context
    A prospective, randomized controlled clinical trial was conducted in 33 Italian surgical departments with the aim of evaluating the efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections.
    Summary · context
    Fifty-four dropped out because of unresectable disease and six were excluded because of protocol violation; the remaining 218 were randomly assigned to the octreotide group (n = 111) or to the placebo group (n = 107).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT02474914

Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy

Mansoura Universityn = 104May 2014 to Apr 2017

Periampullary Carcinoma Resectable

Trial pageClinicalTrials.govUpdated 22 Aug 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.